肺腺癌中LN 5蛋白表达及其与EGFR突变关系的临床研究

目的 探讨肺腺癌组织中层粘连蛋白 5（LN-5）表达及其与人表皮生长因子受体（EGFR）基因突变关系。方法 收集2015年1月至2015年12月57例肺腺癌及其配对癌旁组织标本，采用免疫组化SP法检测LN 5蛋白表达，同时通过液相芯片技术检测EGFR基因突变状态，分析LN 5表达与肺腺癌临床病理特征的关系以及与EGFR基因突变的相关性。结果肺腺癌组织中LN 5蛋白阳性表达率为21.1％（12／57），癌旁组织中为1.7％（1／57），差异有统计学意义（P＜0.05）。EGFR敏感突变（E19+E21）的发生率为43.9％（25／57），EGFR非敏感突变（野生型+E20）的发生率为56.1％（32／57）。LN-5蛋白表达与淋巴结转移和EGFR突变有关（P＜0.05），与TNM分期无关（P＞0.05）。LN 5表达与EGFR突变呈负相关（r=-0.283，P＜0.05）。结论 LN 5在肺腺癌组织中的表达升高，且其表达与EGFR突变状态具有相关性。

Expression of LN 5 in lung adenocarcinoma tissue and its relationship with EGFR mutations

ObjectiveTo investigate the clinical significance of the expression of laminin 5 （LN 5） in lung adenocarcinoma and its relationship with mutations of epidermal growth factor receptor （EGFR）.MethodsFrom January 2015 to December 2015， specimens from 57 cases of lung adenocarcinoma and adjacent normal tissues with pathological confirmation after surgical resection were collected. LN 5 expression was detected using immunohistochemical SP methods， and EGFR mutations were assessed using liquichip technology. The expression of LN 5 and its relationship with EGFR mutations were analyzed.ResultsThe positive expression of LN 5 in adenocarcinoma tissues was 21.1％ （12／57）， higher than 1.7％ （1／57） of adjacent normal tissues （P＜0.05）. The incidence of EGFR mutations （E19+E21） was 43.9％ （25／57）， while that of wild type+E20 was 561％ （32／57）. The expression of LN-5 was associated with lymph node metastasis and EGFR mutation （P＜0.05）， but not with TNM stage （P＞0.05）. There was a negative correlation between the expression of LN-5 and EGFR mutation（r=-0.283，P＜0.05）.ConclusionThe expression of LN 5 is up regulated in lung adenocarcinoma and is correlated with EGFR mutation status.